Kardigan Raises $254 Million Series B to Advance Late-Stage Portfolio of Personalized Cardiovascular Medicines
Financing will drive continued progress of three late-stage programs in specific types of dilated cardiomyopathy, acute severe hypertension, and calcific aortic valve stenosis where no treatments exist New capital reinforces Kardigan’s path to multiple data…